A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Atriomx Health Announces $10 Million Series A Financing-Funds to Be Used for Development and Clinical Study

Atriomx Health Announces $10 Million Series A Financing-Funds To Be Used For Development And Clinical Study

Atriomx Health, a Menlo Park, California-based developer of novel, non-invasive solutions for the detection and characterization of the underlying disease mechanisms of atrial fibrillation and other arrhythmias, announced today that it has secured a $10 million Series A financing.

Atriomx Health notes Ajax Health and Zeus Health will co-lead the Series A round, the proceeds of which will be used to fund initial development and clinical study of the company’s hardware, software, and algorithmic solutions.

“This financing will allow Atriomx to pursue the tremendous opportunity to transform the diagnosis and treatment of atrial fibrillation stemming from the application of novel AF detection and characterization capabilities to data that can be collected non-invasively,” said Duke Rohlen, CEO of Ajax Health and Zeus Health.

In conjunction with the Series A financing, Atriomx Health has appointed Mike Carter to serve as the company’s Chief Operating Officer. Mike brings experience productizing advanced algorithms from Kodiak Robotics, where he was a founding engineer and software lead.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy